BEXTRA

On April 7, 2005, the prescription drug Bextra, used to treat arthritis and pain, was removed from the market by its manufacturer, Pfizer, Inc. at the request of the Food and Drug Administration (FDA). Bextra, a COX-2 inhibitor, has been linked to Stevens Johnson Syndrome, an extreme allergic reaction to skin. Bextra has been shown to increase the risk of heart attacks and strokes associated with blood-clotting problems. Bextra was prescribed for the relief of symptoms of osteoarthritis management of acute pain in adults, treatment of menstrual symptoms, and relief of rheumatoid arthritis symptoms.

Stevens-Johnson Syndrome:

In requesting Pfizer to withdraw Bextra from the market, the FDA cited a risk of serious skin reactions to Bextra, including Stevens-Johnson Syndrome which is potentially life-threatening. Symptoms of Stevens-Johnson Syndrome include:

Flu-like symptoms, including cough, malaise and swelling, and high fever

Skin rash peeling from large areas of the body

Painful blistering of mucous membranes, especially in the mouth, eyes, and vagina.

Severe conjunctivis, iritis, edema, blisters and erosions of the eye

Lesions of gums, tongue, or lips

Sores in the urinary tract

Adverse drug reactions

Another form of skin disease associated with use of Bextra is Toxic Epidermal Necrolysis, also potentially fatal and causes rash, skin peeling, and sores on the mucous membranes.

If you, or a family member, have taken Bextra and think that you or your family member may be suffering from its side effects, please contact Lanham & Blackwell, P.A., for assistance and more information. We are an experienced law firm that can help you in protecting your legal rights and holding negligent parties responsible. .

Additional links concerning Stevens-Johnson Syndrome:
Stevens Johnson Syndrome Foundation

Wrong diagnosis


		BEXTRA (VALDECOXIB) On April 7, 2005, the prescription drug Bextra, used to treat arthritis and pain, was removed from the market by its manufacturer, Pfizer, Inc. at the request of the Food and Drug Administration (FDA). Bextra, a COX-2 inhibitor, has been linked to Stevens Johnson Syndrome, an extreme allergic reaction to skin. Bextra has been shown to increase the risk of heart attacks and strokes associated with blood-clotting problems. Bextra was prescribed for the relief of symptoms of osteoarthritis management of acute pain in adults, treatment of menstrual symptoms, and relief of rheumatoid arthritis symptoms. Stevens-Johnson Syndrome: In requesting Pfizer to withdraw Bextra from the market, the FDA cited a risk of serious skin reactions to Bextra, including Stevens-Johnson Syndrome which is potentially life-threatening. Symptoms of Stevens-Johnson Syndrome include: Flu-like symptoms, including cough, malaise and swelling, and high fever Skin rash peeling from large areas of the body Painful blistering of mucous membranes, especially in the mouth, eyes, and vagina. Severe conjunctivis, iritis, edema, blisters and erosions of the eye Lesions of gums, tongue, or lips Sores in the urinary tract Adverse drug reactions Another form of skin disease associated with use of Bextra is Toxic Epidermal Necrolysis, also potentially fatal and causes rash, skin peeling, and sores on the mucous membranes. If you, or a family member, have taken Bextra and think that you or your family member may be suffering from its side effects, please contact Lanham & Blackwell, P.A., for assistance and more information. We are an experienced law firm that can help you in protecting your legal rights and holding negligent parties responsible. . Additional links concerning Stevens-Johnson Syndrome: Stevens Johnson Syndrome Foundation Wrong diagnosis Contact Us
		©2006 Lanham & Blackwell, P.A. All rights reserved. Site Map Legal Disclaimer